![](jpg/gettyimages-1134798557-150x150.jpg)
Illumina
-
EU Orders Grail Sale; Illumina Continues Appeals But Plans for Multiple Outcomes
European Union regulators ordered Illumina to divest Grail. Illumina is appealing antitrust findings in Europe and the U.S., but the DNA sequencing giant revealed that divesting all or part of Grail is an option even if it wins both legal challenges.
-
Devices & Diagnostics, BioPharma
Europe Imposes Maximum Fine on Illumina for Early Grail Acquisition
Illumina must pay a €432 million fine for closing its Grail acquisition before the European Commission finished its inquiry into the tie-up. The penalty is the maximum amount the regulator can impose on a company for breaching European merger rules.
-
Jorie Healthcare CEO Shares Why Automation is Critical to Revenue Cycle Management
The revenue cycle management business is using AI tools to automate cumbersome tasks to help hospitals operate more efficiently. It’s beginning to attract the attention of major healthcare organizations.
-
Devices & Diagnostics, BioPharma, Legal
FTC Orders Illumina to Divest Grail, Says Deal Stifles Cancer Test Competition
The Federal Trade Commission has ordered Illumina to divest Grail, the liquid biopsy company it acquired for more than $7 billion. The agency said Illumina’s proposed remedies are insufficient and the tie-up is likely to reduce competition in the R&D and commercialization of new cancer tests.
-
PacBio’s latest announcement: The long and short of It
On the first day of American Society of Human Genetics meeting, PacBio rolls out new long and short-read sequencers…music group Maroon 5.
-
Illumina sues former employees turned founders of Guardant Health
DNA sequencing power house Illumina sued liquid biopsy company Guardant Health, whose founders used to work for Illumina, claiming the two stole information from Illumina to file patents for Guardant. Illumina alleges that one of the executives misappropriated confidential information while he was still on Illumina’s payroll.
-
As genetic testing expands, evidence and awareness needed to spur adoption
Genetic tests are becoming available for a wider range of applications. During a CB Insights panel discussion, Phil Febbo of Illumina and Alicia Zhou of Color explained what they think needs to happen to make these tests accessible and affordable for more people.
-
Illumina’s Grail buyout beats deadline, but legal and regulatory hurdles remain
In closing its Grail acquisition before U.S. and European regulators sign off, Illumina is taking a chance the deal will pass regulatory muster. It’s a potentially pricey gambit, as Illumina could face fines for its early action and there are no assurances that regulators will agree that the deal is not anticompetitive.
-
MedCity Influencers, Diagnostics
Would Illumina’s acquisition of GRAIL constrict the expansion of the liquid biopsy space?
The Federal Trade Commission and the European Union are reviewing the soundness of this acquisition. But if Illumina acquires Grail, the company that it spawned back in January 2016, will it squeeze the nascent liquid biopsy market?
-
Illumina’s $7.1B Grail buyout is challenged by FTC on competitive grounds
The Federal Trade Commission is opposing Illumina’s proposed $7.1 billion Grail acquisition, arguing that it will reduce competition for multi-cancer early detection tests. Illumina disagrees with the regulator’s position and will oppose the FTC’s challenge.
-
Navigating Healthcare’s Data Revolution: Priorities, Opportunities, and Challenges for Health Systems
Arcadia recently partnered with HIMSS Market Insights to survey executives, IT, technology, and clinical leaders. Here’s what we found.
-
StartUPDATES: New developments from healthcare startups
Read about news from healthcare startups Carrum Health, Turing, and new companies in the Illumina Accelerator program.
-
Illumina, Helix track spread of more contagious coronavirus variant
The two companies are working together to detect instances of the more contagious B.1.1.7 variant in the U.S. After Colorado identified the first case in the U.S. on Dec. 28, more than 60 cases have since been found across the country.
-
String of FDA approvals gives momentum to liquid biopsies
Following years of research and investment, liquid biopsies are steadily accumulating FDA approvals. The tests are being used in molecular profiling of solid tumors and as companion diagnostics for targeted cancer therapies.
-
A snapshot of the precision medicine landscape
What needs to happen to facilitate data sharing, ensure access to genome sequencing and promising personalized therapies?
-
Faced with slowing demand, 23andMe cuts 100 employees
The DNA testing company confirmed on Thursday that it would lay off about 100 employees. The restructuring was a result of slowing consumer demand.